Treatment of Aortic Insufficiency
Surgical aortic valve replacement (AVR) is indicated for all symptomatic patients with severe aortic regurgitation (AR), regardless of left ventricular ejection fraction (LVEF). 1, 2
Symptomatic Severe AR
For patients presenting with symptoms (dyspnea, angina, syncope) and severe AR, surgery should not be delayed as the condition deteriorates rapidly with high mortality risk 1, 2. This is a Class I, Level B recommendation across all major guidelines.
Asymptomatic Severe AR
The decision tree for asymptomatic patients depends on LVEF and left ventricular dimensions:
With LV Systolic Dysfunction
- LVEF <50%: AVR is indicated (Class I) if no other cause for LV dysfunction is identified 1
- LVEF <55%: AVR is reasonable (Class IIa) in some guidelines 1
With Preserved LVEF
AVR is reasonable when:
- LV end-systolic diameter (LVESD) >50 mm (Class IIa) 1
- LVESD >45 mm may be considered in select patients 1
- Progressive LV dilatation into severe range (LV end-diastolic dimension >65 mm) with declining LVEF on serial studies (Class IIb) 1
Acute Severe AR
This is a surgical emergency. Medical therapy with afterload reduction may stabilize the patient temporarily, but surgery should not be delayed, especially with hypotension, pulmonary edema, or low-flow states 1. Intra-aortic balloon counterpulsation is contraindicated 1.
Medical Management
Chronic AR
For asymptomatic patients with chronic AR and hypertension (systolic BP >140 mmHg):
- ACE inhibitors or dihydropyridine calcium channel blockers are recommended 3, 4, 3
- Avoid beta blockers as they prolong diastolic filling time and may worsen regurgitation 3, 4, 3
For symptomatic patients or those with LV dysfunction but prohibitive surgical risk:
- Guideline-directed medical therapy with ACE inhibitors, ARBs, or sacubitril/valsartan is recommended (Class I) 1
- Diuretics for symptom relief, but use sparingly 1
Important Caveat
Medical therapy does not prevent progression of AR or delay need for surgery in asymptomatic patients—it only treats concurrent hypertension 3, 4, 3. Vasodilators may improve LV performance but have shown variable effects on long-term outcomes like time to valve replacement 3, 4, 3.
Surgical Options
Choice of Procedure
- AVR with mechanical or bioprosthetic valve is standard 1, 2
- Aortic valve repair may be considered in selected patients with favorable anatomy at experienced centers (Class IIb) 1, 2
- Valve-sparing root replacement may be considered in young patients with aortic root dilatation and tricuspid valves when performed by experienced surgeons 2
Concurrent Cardiac Surgery
AVR is indicated (Class I) in patients with severe AR undergoing:
AVR is reasonable (Class IIa) for moderate AR in patients undergoing cardiac surgery for other indications 1
Aortic Root Considerations
When aortic root diameter ≥45 mm and surgery is indicated for severe AR, replacement of aortic sinuses and/or ascending aorta is reasonable at comprehensive valve centers (Class IIa) 1
Transcatheter Options
TAVI should NOT be performed in patients with isolated severe AR who are surgical candidates (Class III) 1. TAVI may be considered in experienced centers for highly selected patients ineligible for surgery, but this remains investigational with limited data 5, 6, 7.
Surveillance
Severe Asymptomatic AR
- Every 6-12 months with echocardiography 1
- Every 3-6 months if significant changes in LVEF or LV dimensions are observed 1
Markers of Severe AR
- Vena contracta ≥0.6 cm
- EROA ≥0.3 cm²
- Regurgitant volume ≥60 mL/beat
- Regurgitant fraction ≥50%
- Holodiastolic flow reversal in descending aorta
- Evidence of LV dilatation 1
Common Pitfalls
- Delaying surgery in symptomatic patients—once symptoms appear, prognosis deteriorates rapidly
- Using beta blockers in chronic AR—these worsen regurgitation by prolonging diastole
- Relying on medical therapy alone in asymptomatic patients—it does not prevent disease progression
- Missing the window for surgery in asymptomatic patients—operate before irreversible LV dysfunction develops (LVEF <50% or LVESD >50 mm)
- Attempting TAVI in isolated AR outside of clinical trials—outcomes remain uncertain and this is not guideline-recommended